Adamant Health teams up with Gerresheimer to improve the care for people with Parkinson's disease
Adamant Health’s technology, using electromyography (EMG), is the first one in the world to reliably measure the impact of medication in patients' motor symptoms, also outside clinic visits, in daily life. Medical doctors can use the technology to decide on more targeted medication, and further, pharma companies can develop better medicine as they now can get real data from the field.
German medtech company Gerresheimer invests in Finnish startup to enable measurements in day-to-day life of people suffering from Parkinson’s disease. Adamant Health and Gerresheimer have great strategic synergies in bringing new and revolutionary solutions to provide better days for people with Parkinson’s disease. Adamant Health secures funding for further developing their Parkinson’s disease Measurement and Analysis Service and entering new markets. In addition to Gerresheimer, existing investors Voima Ventures and Cor Group, together with several angel investors, are participating in the round.
“With this funding, we’re ensuring Adamant Health’s solution’s further development and our ability to bring it into new markets. Our Measurement and Analysis Service – including the CE marked analysis technology – aims to improve the daily life of people with Parkinson’s disease. The service enables physicians to individualize their treatment based on detailed visibility on their patient’s symptoms and overall situation” said Paulus Carpelan, CEO, Adamant Health Ltd. “We are excited, and we’re looking forward to collaborating with Gerresheimer towards our joint vision of improving healthcare outcomes for people with Parkinson’s disease”, he continued.
Adamant Health’s analysis technology uses data from a wearable EMG and motion sensor to provide long-term accurate visibility to motor symptoms typical in Parkinson’s disease. Adamant Health is the only provider in the world of this kind of technology, which can be used in clinical patient care at clinics, as well as at home.
“We see great opportunities in our partnership with Adamant Health. Our common goal is to optimize the personalized treatment of Parkinson’s disease and to improve the patient’s quality of life dramatically,” said Dietmar Siemssen, CEO of Gerresheimer AG. “Our investment will help drive the further development of Adamants unique technology and service. At the same time, it is part of our strategic expansion into innovative, platform-based drug delivery devices and digital disease monitoring”, he added.
To date, Adamant Health has raised 2,2M€ for its seed round in total, and is still looking for 800k€ to complete the round. With the investment, the Adamant Health team are able to continue working towards their end goal - that the technology becomes widely used throughout Parkinson’s care, research and pharma companies for the benefit of everyone suffering from Parkinson’s disease.
Contact information:
Adamant Health Ltd
Paulus Carpelan
CEO, Adamant Health
paulus@adamanthealth.com
+358 50 4867 516
Gerresheimer AG
For Press:
Ueli Utzinger
Group Senior Director Marketing & Communication
+49 211 6181-250
ueli.utzinger@gerresheimer.com
For Investor Relations:
Carolin Nadilo
Corporate Senior Director Investor Relations
+49 211 6181-220
carolin.nadilo@gerresheimer.com